Top Tweets for #Trialdesign
Imaging findings alone accounted for 44.5% of screen failures in one analysis of 87 retina trials.
A new piece argues screening logs are evidence about the protocol, and most are kept in a form nobody can learn from. https://t.co/1MxVeQ5WMo #ClinicalTrials #TrialDesign
Delayed treatment effect predicting (DTEP) model for guiding immuno-oncology trial designs
https://t.co/5rd0oq9vW3
#DelayedTreatmentEffect #ImmunoOncology #TrialDesign #MedTwitter
New #editorial by Thomsen & Legrand discussing the #EPITUBE trial design and biological exposure separation #trialdesign
https://t.co/ubBFZfmgy9
Are epilepsy trials excluding too many patients? This commentary explores time-to-event trial designs to expand access and advance antiseizure medication development.
https://t.co/Bc9olTEi7G
#epilepsy #ILAE #epilepsiajourn #antiseizuremedication #seizurecount #trialdesign
Systematic Review of #TrialDesign and #Endpoints in #LupusNephritis
#VisualAbstract by @RafaelLpezMrqu2
https://t.co/SANwPPoLS5
Need leading experts to design your next global #CV trial? Let's talk. The DCRI brings decades of expertise to every collaboration. Reach out to Claire Beard to schedule a meeting at #ACC26. [email protected] | Learn more: https://t.co/FMz0TkJ9VL #trialdesign #CardioX
@UsNdHealth @NatureCVR @GuiBaudry @slumberbell @jaygirimd @CASivaram1 @BakhshiHooman @NSepehrvand @docprk @aradhanaverma_ @EkateriniL @NicolasGirerd Sometimes, it is not possible to meet GCP requirements with full decentralization. We provide criteria for assessing feasibility of full decentralization, especially when a product label is required, and suggest hybrid decentralized trials in these instances. #TrialDesign
🔜 #ELCC26 @myESMO 🇩🇰
🔥Adaptive escalation and de-escalation treatment for NSCLC
☑️ #Biomarker #DeEscalation #Escalation #TrialDesign
🎙️Chair: @stephanieplsaw @JordiRemon
@OncoAlert @Larvol #LCSM
Left: #valsartan vs placebo in HFrEF (truncated y axis )
Right: #enalapril vs placebo in HFrEF
Same primary outcome
Enalapril/ACEi then considered gold standard in HFrEF
Therefore, appropriate comparator for a new RAASi+ in a #HFrEF RCT in 2009 would be.. ??
#TrialDesign
See also enalapril instead of similar dose valsartan in HFrEF
Predicting Success: How GenBioCa Uses Digital Modelling in Trial Design!
https://t.co/LtwzAYg1WV
Visit https://t.co/nQSCGs8kcp or mail us at [email protected]
#DigitalModelling #TrialDesign #PredictiveAnalytics #ClinicalResearch #Innovation #PharmaTech #GenBioCa
Analysis of 1,935 #GI & pancreatic #NEN shows older #age 👴 & male #sex lead to lower #OS, tumor #mutations,🧬 and immune profiles. Distinct #age & #sex specific patterns may inform future #trialdesign & care #GIonc
@susanebates @gbanna74 @PasRescigno
https://t.co/98qhImZoNK
#RCTs should not be complicated
- simple eligibility
- important outcome
- streamlined follow up / data collection
Sir #MartinLandray in our session on designing efficient trials
(What am I doing on this session, gulp?)
#CVCT2025 #TrialDesign
@djc795 @drjohnm Second issue is the pitfall of composite PEP selection in which there is opposite treatment effect on the component endpoints. Even with a larger trial and/or higher event rates, overall treatment effect would be neutral. #TrialDesign
@JjParienti @GileadSciences @drmoupali PURPOSE 1 & 2: bHIV matches low-adherence HIV rates, more closely in cis women than MSM/TGW—highlighting how population & behavior can skew estimates. Elegant work @JjParienti supporting bHIV as a robust, ethical comparator in PrEP trials. #HIV #PrEP #TrialDesign
Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO
Wearable devices used to define “objective” fitness (OPS) in phase I trials
👉OPS (📸2) better predictor of OS than ECOG-PS (📸3)
🧐Actually, poor ECOG-PS and OPS correlation (📸4)
🔮⌚️#DigitalOncology for #TrialDesign
Excited to share our JCO paper “Objective Performance Status” (OPS), validated with wearables. We established a 1,200 m/day cutoff stratifies metastatic cancer survival (mOS 3.2/11.2;HR 5.76). Grateful to the team and @VicMorenoGarcia for his mentorship
🔗 https://t.co/U54oki1Rnm
Clinical trial #endpoints in pragmatic heart failure #RCTs
Insightful review on selection, classification, and data capture of pragmatic trial endpoints led by @vkittipibul #AdamDevore @DCRINews
🔗 https://t.co/uEBM2jQlcR…
#TrialDesign #ResearchMethods #RCTs
Happening now: the 7th #3CTWorkshop, where several #HFC members will be moderating and presenting!
This high-level think tank brings together global experts to explore trial design, ethics, and innovation in #criticalcare
#ClinicalTrials #TrialDesign #Innovation
I must be at the @franceintheus!
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends..
#3CT #TrialDesign
16/
Cross-overs are not just messy data—they’re design choices that shape trial conclusions.
Understand them.
Scrutinize them.
And don’t let them hijack your outcomes.
📊🔍 #RCT #EBM #TrialDesign #MedTwitter
Last Seen Hashtags on Sotwe
BaitedStraights
Seen from Netherlands
KottaBommaliPS
Seen from United States
teenage #moms
Seen from Turkey
itsummerouting
Seen from United States
Verimob
Seen from Peru
เย็ดพยาบาล
Seen from Thailand
momsonn()*****
Seen from Netherlands
سالب_الرياض
Seen from Spain
eskisehirpasif
Seen from Turkey
اختلاف_كبير
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.6M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.8M followers
Taylor Swift
@taylorswift13
83.7M followers
Lady Gaga
@ladygaga
75.2M followers
Virat Kohli
@imvkohli
73M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66M followers
Bill Gates
@billgates
65M followers
Selena Gomez
@selenagomez
62.8M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers